{
    "2018-05-08": [
        [
            {
                "time": "",
                "original_text": "[强于大市评级]医药行业周报：中美贸易摩擦持续看好医药牛市 推荐智飞生物、康泰生物、贝瑞基因等",
                "features": {
                    "keywords": [
                        "医药",
                        "中美贸易摩擦",
                        "牛市",
                        "智飞生物",
                        "康泰生物",
                        "贝瑞基因"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[增持评级]联讯医药行业2017年报及2018Q1季报总结：行业整体扣非净利增速下降 业绩明显分化下关注结构性机会",
                "features": {
                    "keywords": [
                        "医药",
                        "2017年报",
                        "2018Q1季报",
                        "扣非净利",
                        "增速下降",
                        "业绩分化",
                        "结构性机会"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "医药股表现分化",
                "features": {
                    "keywords": [
                        "医药股",
                        "表现分化"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "[买入评级]智飞生物(300122)：九价HPV疫苗代理权如期落地 业绩爆发可期",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "九价HPV疫苗",
                        "代理权",
                        "业绩爆发"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}